



**BTOG Webinar: ASCO in an Hour 2021**

**Thursday 10<sup>th</sup> June 2021**

**17:30 to 18:30**

**Approved for 1 category 1 (external) CPD credit (code 136022)**

**From the Federation of the Royal Colleges of Physicians of the United Kingdom**

Chair: Dr Tom Newsom-Davis – BTOG Steering Committee Vice-Chair

17:30 Systemic Anti-Cancer Therapy (SACT) Data

Fiona Blackhall

17:45 Systemic Anti-Cancer Therapy (SACT) Data

Riyaz Shah

18:00 Radiotherapy Data

Clive Peedell

18:15 Panel discussion led by Chair

18:30 Close

**Sponsors have provided sponsorship towards this independent webinar programme.**



## **Declarations**

1. BTOG confirms that all speakers will introduce themselves and will include as their 1<sup>st</sup> slide a declaration of conflict of interests and this will be visible to attendees.
2. BTOG confirms there will be a clear view of each speaker's slides. Each speaker will talk to the slides and their voice will accompany the slide discussion (where applicable).
3. BTOG confirms that participants viewing the educational presentations live will be able to submit questions and comments via live webinar chat.
4. BTOG confirms that if RCP approves this live webinar BTOG will provide access via BTOG's online resources and note that CPD will apply to the archived version for four weeks after the event date – we will ensure participants viewing the full archived version will be awarded the appropriate CPD and be issued a certificate of attendance.

## **Biographies**

### **Professor Fiona Blackhall**

Dr Blackhall was educated at St Andrews and Manchester Universities. She began Medical Oncology training at The Christie in 1995 and was awarded a four-year Cancer Research Campaign Research PhD Fellowship for a Clinician in 1997 at the Paterson Institute for Cancer Research, Manchester. Following her PhD she undertook a postdoctoral and clinical fellowship in the field of lung cancer and translational research at Princess Margaret Hospital, University of Toronto and Ontario Cancer Institute, Canada. She returned to the UK in 2003 to complete higher specialist training in oncology and was appointed to consultant at The Christie in 2005. Dr Blackhall then established translational research in lung cancer in collaboration with Professor Caroline Dive (CRUK-Manchester Institute). In 2011 this work was recognised with award of the CRUK translational research prize, and in 2012 Dr Blackhall was awarded Christie Hospital Senior Researcher of the year. Since 2005 she has led a clinical trials portfolio of more than 80 phase I-III trials and has been involved in a number of practice-changing studies delivering promising new drugs and treatment regimens to patients. Dr Blackhall is the clinical lead for lung cancer at The Christie and Manchester Cancer Research Centre (MCRC) lung cancer research strategy lead. She is also the Clinical Trials Theme Lead for the recently established Cancer Research UK Lung Cancer Centre of Excellence which is a recognised research partnership between the University of Manchester and University College London. Dr Blackhall's overall objective is to contribute clinically relevant lung cancer research to improve outcomes for lung cancer.

**Dr Clive Peedell** is Consultant Clinical Oncologist and clinical lead for Radiotherapy at the James Cook University Hospital, Middlesbrough. He specialises in the management of lung cancer and prostate cancer and has a major interest in the development of the Stereotactic Ablative Body Radiotherapy (SABR/SBRT) services, both locally and nationally. He was a founding member of the UK SABR Consortium and has worked with the All Party Parliamentary Group on Radiotherapy to campaign for wider adoption of SABR services in the UK. He is a co-investigator for the ADSCaN trial. He is currently a member of the BTOG Steering Committee.

**Dr Tom Newsom-Davis** is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been a member of the BTOG Steering Committee for the past 2 years, and until recently was part of the National Cancer Research Institute Lung Group and led the RM Partners Cancer Vanguard lung pathway. Dr Newsom-Davis is actively involved in clinical research and has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including BTOG, the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.

**Dr Riyaz Shah** qualified from Guy's and St Thomas Hospitals in 1994 and obtained Membership of the Royal College of Physicians of London in 1997. He completed junior medical training in London and was subsequently awarded an Imperial Cancer Research Fund Clinical Research Fellowship that led to the completion of a PhD from Imperial College/Hammersmith Hospital (1998-2001). His research focused on gene transcriptional irregularities in cancer and gene therapy. Dr Shah completed Medical Oncology training at The Royal Marsden Hospital (2002-2006) before being appointed as a Consultant Medical Oncologist at the Kent Oncology Centre (2006-). He was awarded an ASCO Foundation Merit Award in 2005 for his work in a cancer known as carcinosarcoma.

Dr Shah specialises in thoracic and gastrointestinal malignancies and provides NHS clinics at Darent Valley, Maidstone and Tunbridge Wells Hospitals.

He is active in several local and national committees. At the time of writing he is the Chairman of the Lung Tumour Site Specific Group for the Kent Cancer Collaborative, Lead for Research at KOC, Member of the NCRI Lung Clinical Studies Group and Member of the Thoracic Surgery Clinical Reference Group.

He has a major interest in clinical research and acts as principal investigator on many trials in Kent. He was the UK Chief Investigator of the Lux LUNG 5 trial. He has published widely and is regularly invited to speak at local, national and international meetings.